We are live on ! Find out more
ASND icon

Ascendis Pharma A/S

203 hedge funds and large institutions have $8.28B invested in Ascendis Pharma A/S in 2024 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 75 increasing their positions, 67 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 23

12% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 67

7% more funds holding

Funds holding: 189203 (+14)

6% more funds holding in top 10

Funds holding in top 10: 1617 (+1)

0.19% less ownership

Funds ownership: 105.35%105.16% (-0.19%)

10% less capital invested

Capital invested by funds: $9.19B → $8.28B (-$914M)

52% less call options, than puts

Call options by funds: $21.1M | Put options by funds: $43.9M

Holders
203
Holders Change
+14
Holders Change %
+7.41%
% of All Funds
2.93%
Holding in Top 10
17
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+6.25%
% of All Funds
0.25%
New
38
Increased
75
Reduced
67
Closed
23
Calls
$21.1M
Puts
$43.9M
Net Calls
-$22.8M
Net Calls Change
-$19.3M
Name Holding Trade Value Shares
Change
Change in
Stake
PA
151
Profund Advisors
Maryland
$398K +$11.6K +85 +3%
HighTower Advisors
152
HighTower Advisors
Illinois
$393K +$385K +2,833 New
LPL Financial
153
LPL Financial
California
$392K +$40.3K +296 +11%
SAM
154
Sectoral Asset Management
Quebec, Canada
$364K -$183K -1,345 -34%
GC
155
Gilbert & Cook
Iowa
$357K -$35.6K -262 -9%
VEA
156
Virtus ETF Advisers
New York
$351K -$81.1K -596 -19%
GCM
157
Graham Capital Management
Connecticut
$341K +$340K +2,502 New
QL
158
Quarry LP
New York
$341K +$245K +1,800 +257%
TAMH
159
Taikang Asset Management (HK)
Hong Kong
$341K +$340K +2,500 New
TWC
160
TD Waterhouse Canada
Ontario, Canada
$336K +$319K +2,341 +1,427%
Daiwa Securities Group
161
Daiwa Securities Group
Japan
$316K -$22K -162 -7%
AG
162
Algert Global
California
$297K +$105K +770 +55%
T
163
TOBAM
France
$295K
AI
164
Atria Investments
North Carolina
$278K +$277K +2,037 New
BCP
165
Berylson Capital Partners
Massachusetts
$259K -$95.2K -700 -27%
GC
166
Guggenheim Capital
Illinois
$247K +$247K +1,814 New
Mariner
167
Mariner
Kansas
$221K -$8.44K -62 -4%
RhumbLine Advisers
168
RhumbLine Advisers
Massachusetts
$209K +$19.5K +143 +10%
MAP
169
Moody Aldrich Partners
Massachusetts
$208K
SC
170
Searle & Co
Connecticut
$205K +$204K +1,500 New
CI Investments Inc
171
CI Investments Inc
Ontario, Canada
$184K -$15.9K -117 -8%
CA
172
Clearstead Advisors
Ohio
$159K +$14.8K +109 +10%
Legal & General Group
173
Legal & General Group
United Kingdom
$144K +$25.7K +189 +22%
BCM
174
Barometer Capital Management
Ontario, Canada
$137K -$286K -2,100 -68%
Bessemer Group
175
Bessemer Group
New Jersey
$86K -$33.3K -245 -28%

ASND Hedge Fund Activity: Q2 2024 in Review

203 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q2 2024, worth a combined $8.28B — down 9.9% from $9.19B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new ASND positions and 23 closed out — a net gain of 15 holders — while 75 added to existing stakes and 67 trimmed.

The largest buyer was Westfield Capital Management, adding an estimated $121M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $345M.

  • 203 institutional investors held Ascendis Pharma A/S (ASND) as of Q2 2024, up from 189 in Q1 2024.
  • Funds reported $8.28B of Ascendis Pharma A/S stock for Q2 2024, down 9.9% quarter-over-quarter.
  • 38 funds opened new Ascendis Pharma A/S positions in Q2 2024 and 23 closed out, a net change of +15 holders.
  • The largest Ascendis Pharma A/S buyer in Q2 2024 was Westfield Capital Management, an estimated $121M added.
  • The largest Ascendis Pharma A/S seller in Q2 2024 was T. Rowe Price Investment Management, an estimated $345M sold.

Based on aggregated 13F filings for Q2 2024.